Abstract:Bone loss represents a major unsolved problem in rheumatoid arthritis (RA). The skeletal complications of RA consist of focal bone erosions and periarticular osteoporosis at sites of active inflammation, and generalized bone loss with reduced bone mass. New evidence indicates that osteoclasts are key mediators of all forms of bone loss in RA. TNF-alpha is one of the most potent osteoclastogenic cytokines produced in inflammation and is pivotal in the pathogenesis of RA. Production of tumor necrosis factor-alpha (TNF-alpha) and other proinflammatory cytokines in RA is largely CD4(+) T-cell dependent and mostly a result of interferon-gamma (IFN-gamma) secretion. Synovial T cells contribute to synovitis by secreting IFN-gamma and interleukin (IL)-17 as well as directly interacting with macrophages and fibroblasts through cell-to-cell contact mechanisms. Activated synovial T cells express both membrane-bound and soluble forms of receptor activator of NF-kappaB ligand (RANKL). In rheumatoid synovium, fibroblasts also provide an abundant source of RANKL. Furthermore, TNF-alpha and IL-1 target stromal-osteoblastic cells to increase IL-6, IL-11, and parathyroid hormone-related protein (PTHrP) production as well as expression of RANKL. In the presence of permissive levels of RANKL, TNF-alpha acts directly to stimulate osteoclast differentiation of macrophages and myeloid progenitor cells. In addition, TNF-alpha induces IL-1 release by synovial fibroblasts and macrophages, and IL-1, together with RANKL, is a major survival and activation signal for nascent osteoclasts. Consequently, TNF-alpha and IL-1, acting in concert with RANKL, can powerfully promote osteoclast recruitment, activation, and osteolysis in RA. The most convincing support for this hypothesis has come from in vivo studies of animal models. Protection of bone in the presence of continued inflammation in arthritic rats treated with osteoprotegerin (OPG) supports the concept that osteoclasts mediate bone loss, providing further evidence that OPG protects bone integrity by downregulating osteoclastogenesis and promoting osteoclast apoptosis. Modulation of the RANKL/OPG equilibrium in arthritis may provide additional skeletal benefits, such as chondroprotection. The nexus between T-cell activation, TNF-alpha overproduction, and the RANKL/OPG/RANK ligand-receptor system points to a unifying paradigm for the entire spectrum of skeletal pathology in RA. Strategies that address osteoclastic bone resorption will represent an important new facet of therapy for RA.

Osteoclast differentiation in rheumatoid arthritis

Osteoclasts in arthritis and Th17 cell development

The monocyte-to-osteoclast transition in rheumatoid arthritis: Recent findings

Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis

Regulation of differentiation and generation of osteoclasts in rheumatoid arthritis

Proteomic Changes of Osteoclast Differentiation in Rheumatoid and Psoriatic Arthritis Reveal Functional Differences

The molecular understanding of osteoclast differentiation

F4/80+CD206+ M2-like Macrophages Contribute to Bone Erosion in Collagen-Induced Arthritis by Differentiating into Osteoclasts

Regulation of TNF-Induced Osteoclast Differentiation

Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases

Generation mechanism of RANKL+ effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis

The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis

Osteoclast differentiation by RANKL and OPG signaling pathways

Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts

Osteoclast Differentiation and Gene Regulation

CD14+CD16− Monocytes Are the Main Precursors of Osteoclasts in Rheumatoid Arthritis Via Expressing Tyro3TK

TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors

Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation

Target Role of Monocytes as Key Cells of Innate Immunity in Rheumatoid Arthritis

[Mechanism of bone destruction and the contribution of T lymphocytes]